<?xml version="1.0" encoding="UTF-8"?>
<p id="Par62">For statistical analyses, the results will be compared with a well-defined historical cohort of first-line treatment with pembrolizumab in advanced melanoma (KEYNOTE-006) [
 <xref ref-type="bibr" rid="CR5">5</xref>]. In addition, data will be obtained from the DMTR, which prospectively registers clinical data and HRQoL of all patients with advanced and metastatic melanoma who are treated in the Netherlands [
 <xref ref-type="bibr" rid="CR42">42</xref>].
</p>
